Final Program and Schedule

EDUCATIONAL WORKSHOP: TAILORING CLINICAL TRIALS AND THERAPIES

Chairperson: Raphael Catane, The Chaim Sheba Medical Center, Tel Hashomer, Israel
2:30 p.m.-4:30 p.m.

The Translational Research Cycle: Enhancing the Probability of Success
William N. Hait, Ortho Biotech Oncology Research and Development, a Unit of Johnson and Johnson Research and Development, L.L.D., Raritan, NJ, USA

Prognostic Factors in Diffuse Large B-cell Lymphoma: Present and Future
Izidore Lossos, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

Patient Stratification Strategies in Drug Development
Richard B. Gaynor, Eli Lilly and Company, Indianapolis, IN, USA

KEYNOTE TALKS

5:30 p.m.-7:00 p.m. 

Introduction
Tamar Y. Peretz, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

Biomarker Driven Clinical Trials with Molecular Targeted Agents
José Baselga, Vall d'Hebron University Hospital, Barcelona, Spain

Introduction
Joyce Slingerland, Braman Family Breast Cancer Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA

The Linda Fenner Memorial Lecture
EGFR and HER2: Signaling Mechanisms and Relevance to Cancer Therapy
Yosef Yarden, Weizmann Institute of Science, Rehovot, Israel

SESSION 1: ANGIOGENESIS AND TUMOR MICROENVIRONMENT - PART 1

Chairperson: Isaac P. Witz, Tel Aviv University, Tel Aviv, Israel
8:30 a.m.-10:30 a.m.

The Role of Notch Signaling in Tumor Angiogenesis and Interactions with Hypoxia Signaling Pathways
Adrian L. Harris, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Regulation of in situ to Invasive Breast Carcinoma Transition
Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA, USA

Distinguishing Anti- from Pro-tumorigenic Effects of NF-κB Activation
Yinon Ben-Neriah, Hebrew University Medical School, Jerusalem, Israel

New Targeted Therapies that Exploit the Tumor Microenvironment
Amato Giaccia, Stanford University School of Medicine, Stanford, CA, USA

SESSION 1: ANGIOGENESIS AND TUMOR MICROENVIRONMENT - PART 2

Chairperson: Gera Neufeld, The Rappaport Institute, Haifa, Israel
11:00 a.m.-12:00 p.m.

Targeting Cancer-related Inflammation
Frances R. Balkwill, Barts & The London Queen Mary's School, London, United Kingdom

Anti-VEGF Therapy: Mechanisms of Sensitivity, Resistance, and Toxicity
Herbert I. Hurwitz, Duke University Medical Center, Durham, NC, USA

SESSION 2: IMMUNOLOGICAL ISSUES IN CANCER - PART 1

Chairperson: Roni Apte, Ben-Gurion University of the Negev, Israel 
12:00 p.m.-1:00 p.m.

The Functional Consequences of Regulatory T cell Specificity on the Anti-tumor Immune Response
Hyam I. Levitsky, Johns Hopkins University, Baltimore, MD, USA

Inflammatory Chemokines in Malignancy: Bad Guys on the Move
Adit Ben-Baruch, Tel Aviv University, Tel Aviv, Israel

POSTER SESSION A / LUNCH

1:00 p.m.-3:00 p.m.

SESSION 2: IMMUNOLOGICAL ISSUES IN CANCER - PART 2

Chairperson: Michael Lotem, Hadassah Hebrew University Hospital, Jerusalem, Israel
3:00 p.m.-5:00 p.m.

Regulating T Regulatory Cells and Enhancing Activated T Cells
Samir N. Khlief, National Cancer Institute, Bethesda, MD, USA

Controlling of Immune Response to Stress by Viral and Cellular microRNAs
Ofer Mandelboim, Hebrew University Medical School, Jerusalem, Israel

NKG2D-Mediated Tumor Immunity and Immune Suppression
Thomas Spies, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Role of Tumor-associated Macrophages in Tumor Progression and Response to Chemotherapy
Claire Lewis, University of Sheffield Medical School, Sheffield, United Kingdom

PANEL DISCUSSION ON CHALLENGES IN CLINICAL/TRANSLATIONAL RESEARCH IN ISRAEL

5:00 p.m.-6:00 p.m.

Panelists:

• Gideon Rechavi, The Chaim Sheba Medical Center, Tel Hashomer, Israel
• David Sidransky, Johns Hopkins Medical Institute, Baltimore, MD, USA
• Thomas E. Tichler, Rabin Medical Center and Israeli Society for Clinical Oncology and Radiation Therapy, Petah Tivka, Israel
• Jacob Rowe, Rambam Medical Center, Haifa, Israel

• Susan Band Horowitz, Albert Einstein College of Medicine, Bronx, NY, USA

SESSION 3: DNA DAMAGE AND OTHER CELLULAR STRESS RESPONSES

Co-Chairpersons: Michael B. Kastan, St. Jude Children's Research Hospital, Memphis, TN, USA and Varda Rotter, Weizmann Institute, Rehovot, Israel
8:30 a.m.-10:30 a.m.

The ATM-Mediated DNA Damage Response: Bridging the Lab and the Clinic in Cancer Therapy
Yosef Shiloh, Tel Aviv University, Tel Aviv, Israel

Translating Molecular Mechanisms of DNA Repair into Diagnostic Tools for Risk Assessment and Early Detection of Lung Cancer
Zvi Livneh, Weizmann Institute of Science, Rehovot, Israel

Targeted Therapies for Triple Negative Breast Cancer Based on TP53 Status
Helen Piwnica-Worms, Washington University School of Medicine, St. Louis, MO, USA

Poly(ADP)-Ribose Polymerase (PARP) Inhibition Is Safe and Shows Anti-tumor Activity in BRCA1 and BRCA2 Mutation Carriers
Johann Sebastian de Bono, The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom

SESSION 4: TARGETING SIGNALING PATHWAYS

Chairperson: Abraham Nudelman, Bar-Ilan University, Ramat Gan, Israel
11:00 a.m.-1:00 p.m.

Targeting Invadopodia as a Means to Inhibit Metastatic Growth
Sara A. Courtneidge, Burnham Institute for Medical Research, La Jolla, CA, USA

Targeting Invasion and Metastasis
Margaret Frame, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom

Targeting Receptor Tyrosine Kinases in Breast Cancer
Nancy Hynes, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

From Biologic Mechanisms to Therapy of Cancer: Kinase Inhibitors and HSP90 Inhibitors in GIST and other Genomically Simple Sarcomas
George D. Demetri, Harvard Medical School, Boston, MA

POSTER SESSION B / LUNCH

1:00 p.m.-3:00 p.m.

KEYNOTE ADDRESS

7:00 p.m.-7:45 p.m. 

Introduction
Joseph D. Rosenblatt, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA

Targeting Angiogenesis: From the Laboratory to the Clinic
Napoleone Ferrara, Genentech, Inc., South San Francisco, CA, USA

SESSION 5: IMAGING

Chairperson: Hadassa Degani, Weizmann Institute of Science, Rehovot, Israel
8:30 a.m.-10:30 a.m.

Real-Time Molecular Imaging of Signal Transduction Pathways in vivo
David Piwnica-Worms, Washington University School of Medicine, St. Louis, MO, USA

Functional and Molecular Imaging of Tumor Angiogenesis
Michal Neeman, Weizmann Institute of Science, Rehovot, Israel

New Imaging Biomarkers in Oncology
Peter Choyke, National Cancer Institute, Bethesda, MD, USA

PET in Predicting Tumor Response and Patient Survival: Breast & Cervical Cancers
Farrokh Dehdashti, Washington University School of Medicine, St. Louis, MO, USA 

SESSION 6: GENOMICS AND EPIGENOMICS IN CANCER

Chairperson: Bat-Sheva Kerem, The Hebrew University of Jerusalem, Jerusalem, Israel
11:00 a.m.-1:00 p.m.

Factors Influencing DNA Methyltransferase (DNMT) Expression
George J. Hammons, Philander Smith College, Little Rock, AR, USA

The Orchestration of DNA Methylation in Cancer
Howard Cedar, Hebrew University Medical School, Jerusalem, Israel

Patterns of Somatic Mutation in Human Cancer Genomes
Michael R. Stratton, The Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom

Targeting Histone Deacetylases in Cancer
Victoria Richon, Merck & Company, Inc., Boston, MA, USA

DEPARTURE